Chiesi Keen To Nurture Disruptive Innovation
Italian Group Raising International Profile
Chiesi may not be a big pharma giant but it is very good at spotting early-stage innovative projects and partnering with the likes of Moderna, Protalix and Bioasis to tackle respiratory and rare diseases, CEO Ugo Di Francesco tells Scrip.
You may also be interested in...
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
With the biotech sector awash with public and private capital, companies can carry on longer without needing to link up with a bigger player. Big pharma C-suite leaders have been discussing how their firms sweeten potential deals at BIO Digital.
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.